Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Enrolling by invitation Phase 3 Interventional

A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

ClinicalTrials.gov ID: NCT06431893

Public ClinicalTrials.gov record NCT06431893. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Phase 3 Long-Term Extension (LTE) Study To Assess The Safety, Tolerability, And Efficacy Of Treatment With Pegtibatinase In Participants With Classical Homocystinuria (HCU) Due To Cystathionine Beta Synthase Deficiency (ENSEMBLE)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this long-term extension (LTE) study is to evaluate the safety and efficacy of pegtibatinase in patients with classical homocystinuria (HCU). Patients who are active in the Phase 1/2 COMPOSE study or those who complete the 24 weeks of blinded treatment in the Phase 3 HARMONY are eligible to participate. Participants will be in this clinical study for a minimum of 108 weeks including: * a treatment period of up to 104 weeks * a 4-week safety follow-up period

Study identification

NCT ID
NCT06431893
Recruitment status
Enrolling by invitation
Study type
Interventional
Phase
Phase 3
Lead sponsor
Travere Therapeutics, Inc.
Industry
Enrollment
100 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
5 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 29, 2024
Primary completion
Jul 31, 2030
Completion
Jul 31, 2030
Last update posted
May 27, 2026

2024 – 2030

United States locations

U.S. sites
13
U.S. states
12
U.S. cities
13
Facility City State ZIP Site status
Phoenix Children's Hospital Phoenix Arizona 85006
Yale University School of Medicine New Haven Connecticut 06519
Emory University Atlanta Georgia 30322
Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois 60611
Maine Health Pediatric Specialty Care Portland Maine 04012
Uncommon Cures Chevy Chase Maryland 20815
Icahn School of Medicine at Mount Sinai New York New York 10029
Science 37 - Virtual Site Morrisville North Carolina 27560
Oregon Health and Science University Portland Oregon 97239
The Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh Pittsburgh Pennsylvania 15224
University of Texas Southwestern Medical Center Dallas Texas 75390
Utah Health - The University of Utah Primary Children's Hospital Salt Lake City Utah 84113

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06431893, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 27, 2026 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06431893 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →